Zenas BioPharma, Inc. 8-K

What Happened

• On March 16, 2026, Zenas BioPharma, Inc. (ZBIO) filed a Current Report on Form 8-K (Item 2.02) to announce its financial results for the quarter and the year ended December 31, 2025. The company furnished a press release with those results as Exhibit 99.1 to the 8‑K. The filing states the furnished press release is not “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.

Key Details

• Date of filing/announcement: March 16, 2026.
• Reporting period: quarter and year ended December 31, 2025.
• Press release location: furnished as Exhibit 99.1 to the Form 8‑K.
• Technical exhibit: Inline XBRL cover page (Exhibit 104) was included with the filing.

Why It Matters

• This 8‑K signals Zenas BioPharma has released its latest quarterly and full‑year financial results; investors should read the furnished press release (Exhibit 99.1) for specific metrics such as revenue, net income or loss, cash position, and any management commentary or guidance. The filing itself does not provide the numbers — it serves to notify the market that the detailed results have been published.